Bausch + Lomb Corporation (NYSE:BLCO) Receives $15.56 Consensus PT from Brokerages

Bausch + Lomb Corporation (NYSE:BLCO) has been given a consensus rating of “Hold” by the eleven research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $15.5556.

Several equities analysts recently commented on the stock. Evercore ISI upped their price target on shares of Bausch + Lomb from $15.50 to $16.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Morgan Stanley upped their price target on shares of Bausch + Lomb from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Zacks Research raised shares of Bausch + Lomb to a “hold” rating in a research report on Tuesday, August 12th. Barclays dropped their price target on shares of Bausch + Lomb from $19.00 to $16.00 and set an “equal weight” rating for the company in a research report on Monday, June 9th. Finally, HC Wainwright increased their price objective on shares of Bausch + Lomb from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP boosted its stake in Bausch + Lomb by 210.3% during the 2nd quarter. Engineers Gate Manager LP now owns 31,970 shares of the company’s stock valued at $416,000 after acquiring an additional 21,668 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Bausch + Lomb during the 2nd quarter valued at $592,000. PDT Partners LLC boosted its stake in Bausch + Lomb by 182.3% during the 2nd quarter. PDT Partners LLC now owns 172,209 shares of the company’s stock valued at $2,240,000 after acquiring an additional 111,206 shares during the last quarter. Glenview Capital Management LLC boosted its stake in Bausch + Lomb by 210.8% during the 2nd quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock valued at $20,216,000 after acquiring an additional 1,053,855 shares during the last quarter. Finally, Nebula Research & Development LLC lifted its position in shares of Bausch + Lomb by 54.9% in the 2nd quarter. Nebula Research & Development LLC now owns 64,572 shares of the company’s stock worth $840,000 after buying an additional 22,876 shares during the last quarter. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Bausch + Lomb Stock Up 2.9%

Shares of NYSE BLCO opened at $14.9250 on Monday. Bausch + Lomb has a 12-month low of $10.45 and a 12-month high of $21.69. The company has a market capitalization of $5.28 billion, a PE ratio of -19.13, a price-to-earnings-growth ratio of 1.48 and a beta of 0.62. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.55 and a quick ratio of 0.98. The firm’s 50-day moving average is $13.61 and its two-hundred day moving average is $13.59.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.25 billion. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. Equities analysts anticipate that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.